DelveInsight’s “Graft versus Host Disease (GVHD) - Market Insights, Epidemiology and Market Forecast-2023-Global” report provides an overview of the disease and global historical and forecasted epidemiological data for the diagnosed incident cases of Hematopoietic stem cell transplantations (HSCTs) and Graft Versus Host Disease (GVHD) based upon the sub-types of GVHD along with the type of donor involved in the HSCTs, for the forecast period (2013-2023) in the 7MM.
GVHD is one of the severe complications associated with Hematopoietic stem cell transplantations (HSCTs). DelveInsight forecasts predict an on-going increase in HSCTs in the near future which shall lead to subsequent increase in the patient population of GVHD. According to DelveInsight’s estimates, the total number of diagnosed incident cases of Hematopoietic Stem Cell Transplants (HSCTs) shall increase at a Compound Annual Growth Rate (CAGR) of 2.80% from 2013-2023.
The incident rate of GVHD in unrelated donor (URD) is much higher in comparison to the sibling donors (SD), irrespective of the sub-types i.e., acute GVHD (aGVHD) or chronic GVHD (cGVHD). As per DelveInsight forecasts, the global diagnosed incidence cases of aGVHD in sibling donors and aGVHD in unrelated donors, shall increase at a CAGR of 2.63% and 2.51%, respectively, from 2013-2023. In case of cGVHD, the number of diagnosed incident population cGVHD in sibling donors and cGVHD in unrelated donors for the 7MM is expected to accentuate at a CAGR of 1.96% and 1.57%, respectively, by the end of the year 2023.
The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house Forecast model analysis by Publisher team of industry experts.
Scope
- Report covers the disease overview including pathophysiology, symptoms, diagnosis and disease management.
- It focuses on the risk factors and the historical trends of the diagnosed incident cases of allogeneic Hematopoietic Stem Cell Transplants (HSCTs) (which also includes the cases of first transplants along with the total transplants) in the 7MM.
- The Report also covers the detailed historical and forecasted number of diagnosed incident cases of acute GVHD and chronic GVHD, segmented by the type of donors (Sibling donors and unrelated donors) for the 7MM i.e., U.S., EU5 countries(Germany, France, Italy, Spain and United Kingdom) and Japan from 2013-2023.
'
Graft Versus Host Disease (GVHD)
Disease Definition
Disease Types
Acute GvHD
Chronic GvHD
Grades of GvHD
Pathophysiology
Risk Factors for GVHD
Diagnosis
Epidemiology and Patient Population
Key Points
Global
Total Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) (2013-2023)
Total Diagnosed Incident Cases of aGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs (2013-2023)
Total Diagnosed Incident Cases of cGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs (2013-2023)
United States
Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in United States (2013-2023)
Diagnosed Incident Cases of aGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in United States (2013-2023)
Diagnosed Incident Cases of cGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in United States (2013-2023)
Europe
Germany
Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in Germany (2013-2023)
Diagnosed Incident Cases of aGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Germany (2013-2023)
Diagnosed Incident Cases of cGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Germany (2013-2023)
France
Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in France (2013-2023)
Diagnosed Incident Cases of aGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in France (2013-2023)
Diagnosed Incident Cases of cGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in France (2013-2023)
Spain
Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in Spain (2013-2023)
Diagnosed Incident Cases of aGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Spain (2013-2023)
Diagnosed Incident Cases of cGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Spain (2013-2023)
Italy
Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in Italy (2013-2023)
Diagnosed Incident Cases of aGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Italy (2013-2023)
Diagnosed Incident Cases of cGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Italy (2013-2023)
United Kingdom
Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in United Kingdom (2013-2023)
Diagnosed Incident Cases of aGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in United Kingdom (2013-2023)
Diagnosed Incident Cases of cGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in United Kingdom (2013-2023)
Japan
Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in Japan (2013-2023)
Diagnosed Incident Cases of aGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Japan (2013-2023)
Diagnosed Incident Cases of cGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Japan (2013-2023)
Assumptions and Rationale
Appendix
Report Methodology
Consulting Services
Disclaimer
About DelveInsight
Table 1: Total Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) (2013-2023)
Table 2: Total Diagnosed Incident Cases of aGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs (2013-2023)
Table 3: Total Diagnosed Incident Cases of cGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs (2013-2023)
Table 4: Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in United States (2013-2023)
Table 5: Diagnosed Incident Cases of aGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in United States (2013-2023)
Table 6: Diagnosed Incident Cases of cGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in United States (2013-2023)
Table 7: Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in Germany (2013-2023)
Table 8: Diagnosed Incident Cases of aGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Germany (2013-2023)
Table 9: Diagnosed Incident Cases of cGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Germany (2013-2023)
Table 10: Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in France (2013-2023)
Table 11: Diagnosed Incident Cases of aGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in France (2013-2023)
Table 12: Diagnosed Incident Cases of cGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in France (2013-2023)
Table 13: Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in Spain (2013-2023)
Table 14: Diagnosed Incident Cases of aGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Spain (2013-2023)
Table 15: Diagnosed Incident Cases of cGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Spain (2013-2023)
Table 16: Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in Italy (2013-2023)
Table 17: Diagnosed Incident Cases of aGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Italy (2013-2023)
Table 18: Diagnosed Incident Cases of cGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Italy (2013-2023)
Table 19: Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in United Kingdom (2013-2023)
Table 20: Diagnosed Incident Cases of aGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in United Kingdom (2013-2023)
Table 21: Diagnosed Incident Cases of cGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in United Kingdom (2013-2023)
Table 22: Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in Japan (2013-2023)
Table 23: Diagnosed Incident Cases of aGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Japan (2013-2023)
Table 24: Diagnosed Incident Cases of cGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Japan (2013-2023)
